Latest Breaking News On - Springwork quarterly report - Page 1 : vimarsana.com

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSamantha hilson sandlerChristopherl moertelBetty jayne dahlbergJim cassidyUniversity of minnesota school medicineClinical research divisionAmerican society of clinical oncologyFred hutchinson cancer centerChildren tumor foundationEuropean medicines agencyHealth supervision for children with neurofibromatosis typeNeurofibromatosis programDrug administrationSpringworks therapeutics incDesmoid tumor working group

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of

– Results from pivotal Phase 2b ReNeu trialofmirdametinib in patients with NF1-PN to be presented in an oral presentation –

United statesChristopherl moertelBetty jayne dahlbergJim cassidySamantha hilson sandlerUniversity of washingtonChildren tumor foundationNeurofibromatosis programFred hutchinson cancer centerHealth supervision for children with neurofibromatosis typeEuropean commissionClinical research divisionSpringworks therapeutics incEuropean medicines agencyUs department of commerceAmerican society of clinical oncology

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

– Achieved $21.0 million in OGSIVEO® net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – .

United statesSamantha hilson sandlerSaqib islamEuropean medicines agencyAmerican society of clinical oncologyDrug administrationTrademark officeSpringworks therapeutics incDevelopment rd expensesBeigene ltdEuropean unionWorks therapeuticsChief executive officerBusiness highlightsSupplemental new drug applicationMarketing authorization application

SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J P Morgan Healthcare Conference

STAMFORD, Conn., Jan. 08, 2024 SpringWorks Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42nd Annual.

United statesSamantha hilson sandlerSaqib islamEuropean hematology associationAmgen incBeigene ltdExchange commissionDrug administrationEuropean medicines agencySpringworks therapeutics incAmerican association for cancer researchWorks therapeuticsHealthcare conferenceUnited states foodNew england journalBlinded independent central

SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

STAMFORD, Conn., Dec. 05, 2023 SpringWorks Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an.

New yorkUnited statesSamantha hilson sandlerSpringworks therapeutics incEquity syndicate departmentJp morgan securitiesProspectus departmentGoldman sachs coGuggenheim securitiesDrug administrationBroadridge financial solutionsExchange commissionWorks therapeuticsGoldman sachsIsland avenuePrivate securities litigation reform act